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Inflammatory bowel diseases (IBD) are chronic inflammatory diseases involving all or part of the gastrointestinal tract. The stress-
activated serine-threonine protein kinase D1 (PKD1) protein has previously been implicated in intestinal immune regulation. The
objective of this study was to evaluate the effects of human PKD1 in relation to intestinal inflammation, using a co-culture model
of intestinal epithelial Caco-2 cells and RAW264.7 macrophages. An inflammatory response was induced in the macrophages by
lipopolysaccharide (LPS), upregulating the expression of tumour necrosis factor alpha (TNF-𝛼), interleukin- (IL-) 1𝛽, and IL-6
besides increasing the secretion of TNF-𝛼 protein. The effect of administering PKD1 to Caco-2 was evaluated in relation to both
amelioration of inflammation and the ability to suppress inflammation initiation. Administration of PKD1 (10–100 ng/ml) following
induction of inflammation induced downregulation of TNF-𝛼 expression in RAW264.7 cells. In addition, PKD1 administered for
3 h prior to LPS stimulation reduced the subsequent inflammatory response through downregulation of TNF-𝛼, IL-1𝛽, and IL-
6 in RAW264.7 cells. These results demonstrate a potential role of PKD1 in the intercellular communication between intestinal
epithelial and immune cells, proposing a protective effect of PKD1 on the induction of an inflammatory response in macrophages,
an important aspect during the pathogenesis of IBD.
1. Introduction
IBD including Crohn’s disease (CD) and ulcerative colitis
(UC) are characterized by an impaired intestinal barrier
function and enhanced intestinal inflammation. IBD has
emerged as global diseases with increasing incidence rates
specifically in newly industrialized countries [1]. The patho-
genesis of IBD is related to a decreased intestinal barrier
function, impeding the segregation between the intestinal
epithelial cells (IECs) and the intestinal milieu. Specifically,
an impaired intestinal barrier function is associated with
disease severity in IBD patients [2] as microbes infiltrate
the underlying tissue, inducing inappropriate and exces-
sive activation of the mucosal immune system [3]. Indeed,
inappropriate responses to these external stimuli by immune
cells including dendritic cells and macrophages contribute
to the pathogenesis of IBD as immune and tissue home-
ostasis is disturbed [4]. Reducing inflammation is of utmost
importance in IBD patients and specifically proinflammatory
mediators such as IL-6 and TNF-𝛼 are enhanced in both
CD and UC [5]. Indeed, the immune-regulatory nuclear
transcription factor-kappaB (NF-𝜅B) is strongly activated in
IECs andmacrophages during the course of IBD, augmenting
the secretion of proinflammatory cytokines as TNF-𝛼, IL-1,
IL-6, IL-12, and IL-23 [6]. However, beneficial effects of the
proinflammatory cytokines such as IL-1𝛽, IL-6, and TNF-
𝛼 are also observed in relation to both inflammation and
reepithelialization of wounded intestinal tissue, emphasizing
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Figure 1: Schematic illustration of the co-culture system. Protein
kinase D1 (PKD1) was administered to Caco-2 cells grown for 21
days in transwell inserts, while lipopolysaccharide (LPS)was admin-
istered to RAW264.7 macrophage cells to induce an inflammatory
response.
the importance of temporal control of their expression
to balance appropriate responses to intestinal damage and
inflammation [7–9].
Human PKD1 is a stress-activated protein kinase impli-
cated in signal transduction, cell proliferation, differentiation,
migration, and immune regulation [10]. PKD1 is expressed in
B- and T-cells [11] and activated in RAW264.7 macrophage
cells upon recognition of bacterial pathogen DNA, induc-
ing activation of NF-𝜅B and subsequent expression of the
proinflammatory cytokines, TNF-𝛼, IL-6, IL-8, and IL-12
[12]. Also, PKD1 induces activation of NF-𝜅B in response to
oxidative stress [13], protecting IECs against oxidative-stress-
induced apoptosis [14]. This suggests an important role for
PKD1 in relation to intestinal inflammation. In the present
study we investigated two important questions: (1) Can ad-
ministration of human recombinant PKD1 to IECs ameliorate
an already established inflammatory response in macropha-
ges? (2) Can administration of human recombinant PKD1 to
IECs suppress initiation of a subsequent LPS-induced inflam-
matory response in macrophages? To study these effects, we
employed an in vitro intestinal inflammation model using a
co-culture system with intestinal epithelial Caco-2 cells and
RAW264.7 macrophage cells (Figure 1) [15].
2. Materials and Methods
2.1. Cell Lines and Culturing. The human epithelial colorectal
adenocarcinoma cell line, Caco-2, was kindly donated by Jan
Trige Rasmussen (Aarhus University, Denmark). Cells were
cultivated in Dulbecco’s Modified Eagle Medium (DMEM,
Life Technologies, Denmark) supplemented with 10% fetal
calf serum (FCS, Bio-Whittaker, Denmark), HEPES (10mM,
Life Technologies), GlutaMax (2mM, Life Technologies),
and penicillin-streptomycin (1% v/v, Sigma-Aldrich, Den-
mark). RAW264.7 macrophage cells (ATCC, Germany) were
cultivated in DMEM supplemented with 10% FCS, 2mM
GlutaMax, and 1% v/v penicillin-streptomycin. Cells were
maintained at 37∘C and 5% CO
2
. Caco-2 cells were pas-
saged using 0.05% Trypsin-EDTA (Life Technologies) and
RAW264.7 cells were passaged by scraping off cells when
reaching 80–90% confluence.
2.2. Co-Culture Model. Caco-2 cells (passages 10 to 12) were
seeded at a density of 4.76 × 105 cells/cm2 in polyethylene
terephthalate cell culture inserts with a pore size of 0.4 𝜇m
(BD Falcon, VWR, Denmark) and placed in 6-well cell cul-
ture plates (BD Falcon, VWR, Denmark). Cells were cultured
for 21 days. On day 20, RAW264.7 cells (passages 5 to 8)
were seeded in 6-well cell culture plates at a density of 1.04 ×
105 cells/cm2 in 10% FCS cell culture media. To establish
the co-culture model, Caco-2 inserts were transferred to
RAW264.7 wells on day 21. RAW264.7 cells were stimulated
with 1 𝜇g/ml LPS (Escherichia coli O127:B8, Sigma-Aldrich)
whereas 0.001, 0.1, 10, and 100 ng/ml PKD1 (129.3 kDa,
Thermo Fisher Scientific, Denmark) were added apically to
Caco-2 cells (Figure 1). Two studies were performed, either
LPS was administered for 3 h followed by PKD1 for 3 h or
PKD1 was administered for 3 h followed by LPS for 6 h.
Supernatants were collected and stored at −80∘C for ELISA
analysis, while cells were harvested and stored in RNAlater
at −80∘C for qPCR analysis. Three biological replicas were
performed.
2.3. Transepithelial Electrical Resistance. Triplicate measure-
ments were performed using a Millicell-ERS volt-ohmmeter
combined with a MERSSTX03 electrode (Millipore, Den-
mark) according to the manufacturer’s guidelines. Caco-2
cells were considered fully differentiated once reaching a
stable reading of around 700Ωcm2.
2.4. Enzyme-Linked Immunosorbent Assay. Quantikine
ELISA analysis of murine TNF-𝛼 was performed on
supernatant from RAW264.7 cells. Samples were analysed
in duplicate according to the manufacturer’s guidelines
(R&D systems, AH diagnostics, Denmark). Absorbance was
measured at 450 nm and wavelength corrected at 540 nm
using an EnVision 2103 Multilabel Reader (PerkinElmer,
USA).
2.5. Real-Time Reverse-Transcription PCR. Total RNA was
isolated and purified using the NucleoSpin RNA II kit
according to themanufacturer’s guidelines (Macherey-Nagel,
Germany). Total RNA concentration and purity was assessed
by measuring the absorbance at 260 and 280 nm using a
NanoDrop spectrophotometer. Purified RNA was reverse
transcribed using oligo(dT) 12–18 primers, random primers,
and SuperScript III Reverse Transcriptase (Invitrogen, Den-
mark). cDNA synthesis was performed at 42∘C for 60minutes
followed by reaction inactivation at 70∘C for 15 minutes
on an Esco Swift MaxPro Thermal Cycler (Holm & Halby,
Denmark). cDNA samples were diluted 1 : 10 and standard
samples were diluted 1 : 5. For real-time PCR quantitation a
standard dilution series of 1 : 4 was prepared and analysed
in triplicate, while cDNA samples were analysed in dupli-
cate. The housekeeping gene, hypoxanthine phosphoribosyl
transferase (HPRT1), was quantitated by SYBR GREEN
PCR master mix (Applied Biosystems, Sweden) using the
forward primer: 5󸀠-CAGTCAACGGGCGATATAAAAGTA-
3󸀠 and 5󸀠-CCAGTGTCAATTATATCTTCAACAATCAA-3󸀠
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Table 1: Primers used during PCR quantitation of selected genes in Caco-2 and RAW264.7 cells.
Analysed in the following Gene symbol Gene name Life-Tech. Id. number Organism
Caco-2
TNF-𝛼 Tumor necrosis factor alpha Hs01113624 g1 Homo sapiens
PPARG Peroxisome proliferator-activated receptor gamma Hs01115513 m1 Homo sapiens
IL-10 Interleukin 10 Hs00961622 m1 Homo sapiens
IL-8 C-X-C motif chemokine ligand 8 Hs00174103 m1 Homo sapiens
CTNNB1 Catenin beta 1 Hs00355049 m1 Homo sapiens
RAW264.7
Gapdh Glyceraldehyde-3-phosphate dehydrogenase Mm99999915 g1 Mus musculus
Tnf-𝛼 Tumor necrosis factor alpha Mm00443258 m1 Mus musculus
Il-6 Interleukin 6 Mm00446190 m1 Mus musculus
Il-1𝛽 Interleukin 1 beta Mm00434228 m1 Mus musculus
as the reverse primer. The other selected genes were anal-
ysed by TaqMan Gene Expression Assays consisting of
predesigned unlabelled PCRprimers (Table 1), TaqManMGB
probes labelled with fluorescein amidite (FAM), and TaqMan
Universal Master Mix (Applied Biosystems, Sweden). Fluo-
rescencewas detected using theViaa7 Real-Time PCR System
(Applied Biosystems, Sweden) with 40 cycles as follows:
1.6∘C/s to 95∘C held for 15 sec followed by 1.6∘C/s to 60∘C for
1min. GAPDH and HPRT1 were chosen as the housekeeping
genes for RAW264.7 and Caco-2 cells, respectively.
2.6. Statistical Analyses. Data were analysed using the
MIXEDprocedure of Statistical Analysis Software (SAS Insti-
tute Inc., USA, version 9.3). Mean Ct values of GAPDH or
HPRT1 were used to normalize transcription of the target
genes for RAW264.7 and Caco-2 cells, respectively. Real-
time RT-PCR data are presented as LSMEANS with 95%
confidence intervals, relative to the unstimulated negative
control (=1) of replicate experiments. Results from ELISA are
presented as LSMEANS ± standard error of the mean (SEM)
of replicate experiments. Significant differences were judged
at 𝑃 < 0.05.
3. Results
3.1. PKD1 Stimulates Secretion of TNF-𝛼 from RAW264.7
Cells. To evaluate the immunological response of PKD1 we
employed the already established co-culture model with
intestinal epithelial Caco-2 cells and RAW264.7 macrophage
cells [15–18]. Caco-2 cells were grown for 21 days until
forming a confluentmonolayer of enterocyte-like cells [19], at
which point a co-culture with RAW264.7 macrophages were
established, enabling crosstalk between the two individual
cell monolayers (Figure 1). RAW264.7 macrophages were
stimulated with LPS at a concentration of 1 𝜇g/ml for 6 h,
reaching maximum TNF-𝛼 secretion within a 24 h period
(data not shown). Various concentrations of PKD1 protein
were administered apically to Caco-2 cells either before or
after stimulation of RAW264.7 cells with LPS. This enabled
us to study the ability of PKD1 to ameliorate an already estab-
lished inflammatory response as well as the ability to suppress
initiation of an inflammatory response subsequently induced
by LPS.
Stimulation with LPS induced an inflammatory response
in RAW264.7 cells within 6 h as observed by secretion of
TNF-𝛼 at a concentration of approximately 11.5 ng/ml into the
basolateral compartment (Figure 2). During this 6 h period
of LPS stimulation, the integrity of the Caco-2 monolayer
remained stable (data not shown). Administration of PKD1
to Caco-2 cells prior to stimulation with LPS induced TNF-𝛼
secretion at all concentrations (𝑃 < 0.05). In contrast, PKD1
administered following stimulation with LPS induced TNF-𝛼
secretion at only 0.1 ng/ml of PKD1.
3.2. Effect of PKD1 on the Expression of InflammatoryMarkers.
To evaluate the effect of the various treatments, mRNA from
Caco-2 and RAW264.7 cells were isolated and the expression
of selected genes was evaluated by real-time RT-PCR. The
inflammatory response induced by LPS in RAW264.7 cells
was confirmed by upregulated expression of IL-1𝛽, IL-6,
and TNF-𝛼 when compared with the unstimulated control
(Figures 3(a)–3(c)). Specifically, a considerable upregulation
of both IL-6 and IL-1𝛽 expression levels was observed (>5,000
times).
Treatment with PKD1 in the LPS-stimulated Caco-
2/RAW264.7 co-culture caused alterations in the expression
of TNF-𝛼, whereas IL-1𝛽 and IL-6, in RAW264.7 cells,
remained unchanged during treatment with PKD1 (Figures
3(a)–3(c)). A concentration-dependent effect on TNF-𝛼 was
observed with low concentrations of PKD1 (0.001–0.1 ng/ml)
upregulating TNF-𝛼 expression and high concentrations
of PKD1 (10–100 ng/ml) downregulating the expression of
TNF-𝛼 when compared with the LPS control (𝑃 < 0.05,
Figure 3(c)). Interestingly, the observed effect on TNF-𝛼
expression levels was independent on the order of PKD1,
as a similar concentration-dependent effect was seen, when
administering PKD1 prior to LPS stimulation in RAW264.7
cells. Similarly, administration of PKD1 prior to LPS down-
regulated the expression of IL-1𝛽 (100 ng/ml) and IL-6
(0.001–100 ng/ml), when comparedwith the LPS control (𝑃 <
0.05) in RAW264.7 cells (Figures 3(a) and 3(b)).
Whereas the inflammatory response initiated in
RAW264.7 cells stimulated an immune response in the Caco-
2 cells as observed by an upregulated expression of IL-8 and
TNF-𝛼, only minor differential effects were observed with
PKD1 (Figures 4(a)–4(d)). The effect of PKD1 on the ex-
pression of IL-8, 𝛽-catenin, and PPAR-𝛾 in Caco-2 cells was
nonsignificantly affected, whereas treatmentwith 0.1 ng/ml of
PKD1 after stimulation with LPS upregulated the expression
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Figure 2: PKD1 stimulate secretion of TNF-𝛼 from LPS-stimulated RAW264.7 cells. Protein kinase D1 (PKD1; 0.001, 0.1, 10, 100 ng/ml)
was administered apically to Caco-2 cells in co-culture with RAW264.7 cells. An inflammatory response was induced in RAW264.7 cells
with 1 𝜇g/ml lipopolysaccharide (LPS, E. coli: O127). Effects of PKD1 on secretion of TNF-𝛼 from RAW264.7 cells were evaluated in two
different situations: (◼) LPS was administered to RAW264.7 cells for 3 h, followed by PKD1 to Caco-2 cells for 3 h to investigate whether
PKD1 can ameliorate an already induced inflammation. (◻) PKD1 was administered to Caco-2 cells for 3 h at which point RAW264.7 cells
were stimulatedwith LPS for 6 h to evaluate whether PKD1 can suppress inflammation initiation. TNF-𝛼 level in controls (no LPS stimulation)
was undetectable (ND). Data are presented as means ± SEM (𝑛 = 3). Significant differences (𝑃 < 0.05) within concentrations of PKD1 are
indicated by the lowercase letters.
of TNF-𝛼 when compared with the LPS control in Caco-2
cells (𝑃 < 0.05).
4. Discussion
4.1. LPS Stimulated an Inflammatory Response in Caco-2 and
RAW264.7 Cells. To evaluate the effect of PKD1 in relation
to intestinal inflammation we employed a co-culture model
with intestinal epithelial Caco-2 cells and LPS-stimulated
RAW264.7 macrophages to resemble gut inflammation, as
previously observed [16–18]. Tanoue et al. demonstrated
crosstalk between these cells, as LPS-stimulated RAW264.7
cells secrete TNF-𝛼, thereby inducing IL-8mRNA expression
in Caco-2 cells [15]. In agreement, we observed LPS-induced
secretion of TNF-𝛼 (11.5 ng/ml) in RAW264.7 cells when
RAW264.7 cells were stimulated with 1 𝜇g/ml of LPS (E. coli
O127, Figure 2). Also, an upregulated expression of TNF-𝛼,
IL-6, and IL-1𝛽 was observed in RAW264.7 cells (Figures
3(a)–3(c)). Varying concentrations of LPS have been used for
inducing an inflammatory response. Tanoue et al. reported
the secretion of 50 ng/ml of TNF-𝛼 when stimulating with
100 ng/ml of LPS (E. coli O127) for 3 h [15], whereas 5 ng/ml
of LPS (E. coli O127) for 3 h induced secretion of TNF-𝛼
levels at 350 pg/ml [16].These differential responses might be
explained by varying cell densities aswell as different passages
of RAW264.7 cells employed in the studies, potentially
influencing the responses to LPS stimulation. Concomitantly,
LPS stimulation of RAW264.7 cells induced an upregulated
expression of IL-8 and TNF-𝛼 in Caco-2 cells (Figures 4(a)-
4(b)). Specifically expression of IL-8 in Caco-2 cells was
induced by almost 4-fold when stimulated with 1𝜇g/ml of
LPS, a substantial increase compared to the 2-fold induction
observed byTanoue et al., when stimulatingwith 100 ng/ml of
LPS [15]. Since previous studies have identifiedCaco-2 cells as
unresponsive to LPS [20], these results strongly indicate that
RAW264.7 macrophage cells stimulated with LPS induce an
inflammatory response in the Caco-2 cells through crosstalk
between the two individual cell layers.
4.2. PKD1 Displays a Concentration-Dependent Effect in the
Amelioration of Intestinal Inflammation. To test the abil-
ity of PKD1 protein to ameliorate intestinal inflammation,
RAW264.7 cells were stimulated with LPS for 3 h. This was
followed by administration of PKD1 to Caco-2 monolayers
for 3 h. Whereas no effects were observed on IL-1𝛽 and IL-
6 in RAW264.7 cells, a concentration-dependent effect on
TNF-𝛼 expression levels were observed. Here administration
of 10–100 ng/ml of PKD1 downregulated TNF-𝛼, whereas
lower concentrations (0.001–0.1 ng/ml) caused upregulation
of TNF-𝛼 in RAW264.7 cells. However, a comparable effect
was not observed on the secretion of TNF-𝛼 (Figure 2),
indicating that the observed transcriptional effects did not
directly translate into corresponding effects at the protein
level during this 6 h time period. Since anti-TNF-𝛼 treatment
has emerged as the central target to ameliorate IBD [21], this
emphasizes the potential importance of the observed PKD1-
induced downregulation of TNF-𝛼 in RAW264.7 cells. How-
ever, PKD1 (0.1 ng/ml) upregulated the expression of TNF-
𝛼 in Caco-2 cells (Figure 4(b)), demonstrating a detrimental
effect to the IECs when treated with PKD1. However, due to
the limited effects observed in Caco-2 cells, other potential
mediators induced upon PKD1 treatment might exert the
effects observed in the RAW264.7 cells.
4.3. PKD1 Affects the Initiation of Intestinal Inflammation.
The ability of PKD1 to hamper inflammation initiation was
investigated by administering PKD1 to Caco-2 cells for
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Figure 3: Effect of PKD1 on IL-1𝛽, IL-6, and TNF-𝛼mRNA expression in RAW264.7 cells. Protein kinase D1 (PKD1; 0.001, 0.1, 10, 100 ng/ml)
was administered apically to Caco-2 cells in co-culture with RAW264.7 cells. An inflammatory response was induced in RAW264.7 cells with
1 𝜇g/ml lipopolysaccharide (LPS, E. coli: O127). Effects of PKD1 on IL-1𝛽, IL-6, and TNF-𝛼 expression levels were evaluated in two different
situations: (◼) LPS was administered to RAW264.7 cells for 3 h, followed by PKD1 to Caco-2 cells for 3 h to investigate whether PKD1 can
ameliorate an already established inflammation. (◻) PKD1 was administered to Caco-2 cells for 3 h at which point RAW264.7 cells were
stimulated with LPS for 6 h to evaluate whether PKD1 can suppress inflammation initiation. Data are presented as mean transcriptional levels
relative to the negative control (0% FCS, unstimulated) with 95% confidence intervals (𝑛 = 3). Significant differences (𝑃 < 0.05) within
concentrations of PKD1 and LPS are indicated by the uppercase letters.
3 h prior to a 6 h LPS stimulation in RAW264.7 cells. In
RAW264.7 cells, administration of PKD1 to Caco-2 cells
suppressed the LPS-induced inflammatory response as IL-1𝛽
(100 ng/ml PKD1), IL-6 (0.001–100 ng/ml PKD1), and TNF-𝛼
(10–100 ng/ml PKD1) expression levels were downregulated.
Specifically, a concentration-dependent downregulation of
IL-6 was observed. The proinflammatory cytokine IL-6 is
augmented in acute and chronic wounds [7] and implicated
in the course of IBD [22]. This PKD1-dependent downreg-
ulation therefore demonstrates a potential important effect
of PKD1 in hampering intestinal inflammation. The TNF-𝛼
response observed in RAW264.7 cells with low PKD1 levels
upregulating and high levels downregulating TNF-𝛼 mRNA
levels signifies this concentration-dependent effect of PKD1
observed. Interestingly, secretion of TNF-𝛼 was induced
significantly from the LPS control with no dependency on the
concentration of PKD1 (Figure 2). Administration of PKD1 to
Caco-2 cells induced TNF-𝛼 secretion from RAW264.7 cells,
while downregulating the mRNA expression at 10–100 ng/ml
of PKD1. Hence, the observed effects on the mRNA and
protein levels did not directly associate with each other. Since
TNF-𝛼 mRNA and protein levels were evaluated at identical
times, these variations might be seen as transcriptional alter-
ations translate into effects at the protein level with a certain
delay, limiting the comparability between the two analyses.
Interestingly, PKD1 has previously been found to induce
the expression of TNF-𝛼 and IL-6 in RAW264.7 cells upon
stimulation with bacterial DNA [12]. The downregulation
observed in this study therefore represents a differential effect
of PKD1 once administered to the Caco-2 cells prior to
initiation of inflammation.
Prostaglandin from LPS-stimulated macrophages indu-
ces stimulation of PPAR-𝛾 and late activation of IL-10 at 72 h
in IECs [23].Here, changes in the TEER (data not shown)
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Figure 4: Effect of PKD1 on IL-8, TNF-𝛼, 𝛽-catenin, and PPAR-𝛾 mRNA expression in Caco-2 cells. Protein kinase D1 (PKD1; 0.001, 0.1,
10, 100 ng/ml) was administered apically to Caco-2 cells in co-culture with RAW264.7 cells. An inflammatory response was induced in
RAW264.7 cells with 1𝜇g/ml lipopolysaccharide (LPS, E. coli: O127). Effects of PKD1 on IL-8, TNF-𝛼, 𝛽-catenin, and PPAR-𝛾 expression
levels were evaluated in two different situations: (◼) LPS was administered to RAW264.7 cells for 3 h, followed by PKD1 to Caco-2 cells for 3 h
to investigate whether PKD1 can ameliorate an already established inflammation. (◻) PKD1 was administered to Caco-2 cells for 3 h at which
point RAW264.7 cells were stimulated with LPS for 6 h to evaluate whether PKD1 can suppress inflammation initiation. Data are presented
as mean transcriptional levels relative to the negative control (0% FCS, unstimulated) with 95% confidence intervals (𝑛 = 3). Significant
differences (𝑃 < 0.05) within concentrations of PKD1 and LPS are indicated by the uppercase letters.
and the expression of PPAR-𝛾 in Caco-2 cells remained
unchanged. Similarly, 𝛽-catenin, a major component in the
formation of adherens junctions (AJs) [24], remained unaf-
fected during the various treatments, despite previous obser-
vations of crosstalk between PKD1 and 𝛽-catenin [25, 26].
Consequently, the studies presented here indicate that a
6 h treatment period with LPS is insufficient for evaluating
inflammation-induced effects on 𝛽-catenin and PPAR-𝛾 in
Caco-2 cells. Importantly, we did not evaluate the level of
PKD1 in the RAW264.7 cell supernatant.The effects observed
in the macrophages might therefore be caused by either
an indirect or a direct effect, depending on whether PKD1
penetrated the Caco-2 cells and the transwell inserts, entering
the lower compartment.
Expression of IL-8 and TNF-𝛼 in Caco-2 cells was unaf-
fected by the various treatments, implying that either the
expression was affected during other time periods or other
cellular mediators might be affected by PKD1. Importantly,
from these studies it seems that PKD1 has limited effects once
an inflammatory response has been initiated. This indicates
that the potential anti-inflammatory effect of PKD1 is unable
to affect the severe proinflammatory response initiated in
RAW264.7 cells upon stimulation with LPS. Oppositely,
it seems that a preventive treatment with PKD1 has the
ability to hamper a subsequent proinflammatory response
induced in the macrophages. However, we have to consider
the difference between the periods of PKD1 treatment in
the two studies. Whereas the preventive PKD1 treatment
was administered for 3 h prior to the 6 h LPS stimulation,
giving a total of 9 h treatment with PKD1, Caco-2 cells were
only treated with PKD1 for a total of 3 h when studying
the ability to ameliorate an already established inflammatory
response. Since the inflammationwas initiated 3 h prior to the
treatment with PKD1, the inflammatory response initiated
might be too strong for PKD1 to cause significant effects
during a 3 h period.
In conclusion, PKD1 ameliorated an on-going intestinal
inflammation in the Caco-2/RAW264.7 co-culture at high
concentrations of PKD1, through downregulation of the prin-
cipal proinflammatory cytokine, TNF-𝛼. In contrast, PKD1
administered prior to initiation of an inflammatory response
revealed a concentration-dependent anti-inflammatory effect
through downregulation of the proinflammatory mediators,
IL-6 and TNF-𝛼. The studies provide evidence for a potential
beneficial and protective effect of PKD1 in relation to intesti-
nal inflammation.
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